Gaudium IVF & Women Health Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following Board approval on March 18, 2026. The healthcare company, specializing in IVF and women's health services, reported its first earnings following the successful IPO listing on February 27, 2026, demonstrating strong consolidated performance with significant year-over-year growth.

Regulatory Compliance and Press Release

The Board of Directors meeting commenced at 4:15 p.m. IST and concluded at 6:05 p.m. IST on March 18, 2026. The results were prepared in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and subject to limited review by S K G N & Associates LLP, the company's statutory auditors.

Pursuant to Regulation 30 of SEBI Listing Regulations, the company issued an official press release on March 19, 2026, announcing its Q3 FY26 financial performance. The press release highlighted the company's position as a leading fertility and women's healthcare platform in India, emphasizing its focus on building a scalable, outcome-driven fertility care platform.

Consolidated Financial Performance Shows Strong Growth

The consolidated financial results demonstrated robust performance metrics with significant year-over-year improvements across key parameters. For Q3 FY26, consolidated revenue from operations reached ₹245.07 crores compared to ₹144.00 crores in the corresponding quarter of the previous year.

For the nine-month period ended December 31, 2025, the company achieved revenue from operations of ₹740.06 crores with net profit of ₹161.49 crores, reflecting strong business expansion through its subsidiary structure.

Post-IPO Milestone and Market Listing

Subsequent to the quarter ended December 31, 2025, the company successfully completed its Initial Public Offering (IPO) raising approximately ₹1,650.01 crores. The IPO comprised 2,08,86,200 equity shares of face value ₹5 each at an issue price of ₹79 per share, with an offer for sale component of 94,93,700 equity shares amounting to ₹750.00 crores.

The company's equity shares were listed on the National Stock Exchange of India Limited and BSE Limited on February 27, 2026, marking a significant milestone in its corporate journey and strengthening its position as a differentiated platform in the fertility care segment.

Management Commentary and Business Outlook

Commenting on the performance, Dr. Manika Khanna, Chairperson and Managing Director, emphasized the company's strategic positioning in the fertility care market. She highlighted that the results reflect a category coming of age, with Gaudium IVF at the forefront of shaping the fertility care landscape in India.

The company maintains a paid-up equity share capital of ₹306.97 crores with a face value of ₹5 per share, operating primarily in the healthcare business segment with focus on IVF and women's health services as its core business area.

Nine-Month Performance and Financial Position

The nine-month consolidated results showed total income of ₹743.60 crores and profit before tax of ₹217.46 crores, demonstrating the company's expanded business operations and operational efficiency. The company combines clinical excellence with standardized protocols and technology-led interventions to deliver consistent patient outcomes at scale.

Founded in 2009, Gaudium IVF operates advanced reproductive solutions centers across major Indian cities, offering comprehensive services including high-risk pregnancy care and minimally invasive gynecological procedures, supported by integrated pregnancy care and 24/7 patient services.

Gaudium IVF & Women Health Limited has announced the appointment of new Internal and Secretarial Auditors for the financial year 2025-2026, following a Board of Directors meeting held on March 18, 2026. The appointments were made based on recommendations from the company's Audit Committee and comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board of Directors meeting commenced at 4:15 p.m. (IST) and concluded at 06:05 p.m. (IST) on March 18, 2026. The company has formally notified both BSE Limited and National Stock Exchange of India Limited about these appointments as required under Regulation 30 of SEBI regulations.

Internal Auditor Appointment

The board approved the appointment of M/s. Ram Rattan & Associates, Chartered Accountants as Internal Auditors for the financial year 2025-2026. The following table summarizes the key details:

Ram Rattan & Associates is a New Delhi-based Chartered Accountancy firm led by Founder and Managing Partner, FCA Ram Rattan Gupta. The firm has been peer-reviewed since inception and provides comprehensive services including Lead Advisory, Direct & Indirect Tax Consultancy, Audit & Assurance, Restructuring, Startup Recognition, Financing, Valuation, and Back-Office Support.

Secretarial Auditor Appointment

The company also appointed M/s. Suresh Nainwal & Company, Practicing Company Secretaries as Secretarial Auditors for the financial year 2025-2026 until the date of the ensuing Annual General Meeting.

Firm Expertise and Services

Suresh Nainwal & Company is a proprietorship and peer-reviewed firm with over 6 years of experience in delivering legal and secretarial services to leading corporates. The proprietor, Mr. Suresh Chandra Nainwal, is also a Designated Partner of SGS Associates LLP, Practicing Company Secretaries.

The firm's expertise includes:

• Board management and compliance management
• Committee management and secretarial department management
• Companies Act and SEBI guidelines compliance
• Issue of Bonus Shares, Right Issue, Private Placement
• Annual General Meeting management
• Mergers and acquisitions
• Liaison with Registrar and Share Transfer Agents, Depositories & Stock Exchanges

Regulatory Compliance

Both appointments have been made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30. The company has provided detailed annexures with complete information about both appointments as required by the regulations. The information will also be uploaded on the company's website for public access.